Kowa Company Limited

Junya Tagashira

Seiichi Sato

Toru Miura

Tadaaki Ohgiya

Hiroyuki Ishiwata

Gen Watanabe

Ryohei Sekimoto

Rie Ishida

Hitomi Aoki

Hajime Yamada

Takahiro Kitamura

Takeshi Doi

Toshiharu Morimoto

Masanori Ashikawa

Tatsuaki Nishiyama

Syunji Takemura

Akiyasu Koketsu

Satoshi Goda

Masaki Yamabi

Toshiaki Watanabe

Tetsuya Ishikawa

Takuya Hara

Takahiro Ito

Kazuhiro Onogi

Mototsugu Kabeya

Shunji Takemura

Toru Kanke

Kyoko Yasuoka

Toshiharu Arai

Yoshiharu Miyake

The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPAR&#x3b3; activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C&#x2014;Ror a nitrogen atom; Rrepresents an alkyl group; Rrepresents an alkyl group or a cycloalkyl group; and R, R, and Reach independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar. 

Phenylpyridine derivative and drug containing same

Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R, R, R, Rand Rindependently represent a hydrogen atom, a Calkyl group, or the like; R, R, R, R, R, Rand Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, or the like; A represents N&#x2014;R, a sulfur atom, or an oxygen atom; Rrepresents a hydrogen atom, a Calkyl group, or the like; B represents a Caryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient

Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R, R, R, Rand R' independently represent a hydrogen atom, a Calkyl group, or the like; R, R, R, R, R, Rand Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, or the like; A represents N&#x2014;R, a sulfur atom, or an oxygen atom; Rrepresents a hydrogen atom, a Calkyl group, or the like; B represents a Caryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPAR&#x3b3;-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C&#x2014;Ror a nitrogen atom; Rrepresents a Calkyl group; Rrepresents a Calkyl group or a Ccycloalkyl group; and R, R, Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, a halo-Calkyl group, or a Calkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

Phenylpyridine derivative and medicinal agent comprising same

Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPAR&#x3b3; activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; Rand Rindependently represent a Calkyl group; and each of Rto Ris absent or represents H, a halogen atom, OH, NO, a halo-Calkyl group, a (substituted) Calkoxy group, a (substituted) Ccycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]

Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same

The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

Tetrahydroisoquinoline compound

Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein Ris hydrogen, halogeno, or a group represented by the general formula (2): (wherein Ris straight-chain or branched Calkylene or the like; and Rand Rtogether with the nitrogen atom adjacent to them form a 5- to 7-membered ring); Ris straight-chain or branched Calkyl or the like; Rand Rare each independently hydrogen, one to three halogen atoms, or the like; and A-A-Ais a tripeptide residue composed of &#x3b1;-amino acids each independently selected from the group consisting of glycine, alanine, cyclohexylalanine, and so on.

PAR-2 antagonists

Growing community of inventors

Tokyo, Japan

Junya Tagashira